MELBOURNE, Australia, 11 Oct. 2021 – Promising early signs for cannabis franchise pioneers, Releaf Group, with their Clinic and Dispensaries division showing 100% growth for the September quarter compared with the previous June quarter.
Annualised revenues for Releaf Group’s pioneer clinic and dispensary in Acland Street St Kilda are on target to exceed $7 million for the 2022 financial year, with flower sales now making up over 60% of all products dispensed.
“We have seen a significant increase in patient enquiries. As well as growth in the dispensing of dried flower that is reflective of TGA approvals with dried flower cannabis prescriptions seeing 5,480 prescriptions approved in the month of September”, said Gary Mackenzie, Releaf Group CEO.
September’s figure was more than double that of the same month last year and up sharply from 10,791 in August. As of September 30, there were 430 Authorised Prescribers. Overall, more than 170,00 SAS-B applications have now been approved by the TGA.
Releaf are currently building six new franchises in Queensland with plans to commence their Franchise rollout in NSW, SA and WA as covid lockdowns ease in coming months across the country.
About Releaf: Releaf Group Ltd is the first dedicated and leading medicinal cannabis Clinic and Dispensary Franchise Group in the APAC region. The company’s vertically integrated “seed-to-sale” operations have commenced an aggressive rollout of their Clinic and Dispensary Franchise Model across Australia, New Zealand, and the United Kingdom.